Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Chronic kidney disease
•
Nephrology
Do you recommend delaying spot urine protein quantification testing until after nephrostomy tube removal in a patient with obstructive uropathy?
Answer from: at Community Practice
Yes, if the tubes are coming out. Would not want to make treatment decisions under these circumstances. Not an emergency usually.
Sign In
or
Register
to read more
Answer from: at Academic Institution
Not necessarily. I don't think it would affect it much.
Sign In
or
Register
to read more
26903
26910
Related Questions
Do you avoid prescribing thiazide diuretics for hypertension management in ADPKD patients, given concerns about vasopressin release?
Do you recommend hydrochlorothiazide to manage polyuria in patients with ADPKD who are on tolvaptan?
When would you pursue a kidney biopsy for patients with inflammatory bowel disease who have non-proteinuric progressive CKD of unknown etiology?
Do you recommend avoiding SGLT2i use for patients with proteinuria from diabetic kidney disease if they have urinary retention requiring catheterization?
Would you avoid using cephalosporins in a patient with a history of cephalosporin neurotoxicity in the setting of CKD?
Do you recommend temporarily holding SGLT2 inhibitors in patients with CKD who are undergoing CT imaging with intravenous contrast?
Under what circumstances would you initiate hemodialysis for fetal protection in a pregnant patient with CKD Stage 4 who does not have any usual indications to start dialysis?
Would you start patiromer in a patient with CKD who has persistent hyperkalemia despite taking sodium zirconium cyclosilicate and adherence to a low potassium diet?
Would you consider using acetazolamide to manage glomerular hyperfiltration in patients with type 1 diabetes, since SGLT2 inhibitors are contraindicated in this population?
Under what circumstances would you use tenapanor over more frequently prescribed phosphorus binders for managing hyperphosphatemia in CKD patients?